MEI Pharma Inc. (MEIP) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for MEIP in the last 30 days. The most recent was published Sep 15, 2025.
Latest news
25 items- SECMEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Lite Strategy, Inc. (0001262104) (Filer)
- INSIDERNew insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)3 - Lite Strategy, Inc. (0001262104) (Issuer)
- SECMEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MEI Pharma, Inc. (0001262104) (Filer)
- PRMEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'Lite Strategy Rebrand Aligns with Company's LTC Digital Asset Treasury Strategy Advised by GSR Ventures MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or the "Company") today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's expansion into a pioneer in digital asset treasury management. Alongside the rebrand, the Company's ticker symbol on the NASDAQ Stock Market will transition from MEIP to LITS, effective at market open on September 11, 2025. The rebranding to Lite Strategy, Inc. underscores the Company's commitment to building a long-term corporate strategy around Litecoin (LTC) as our primary reserve asset. In August, MEI became the first U.S.-
- SECSEC Form EFFECT filed by MEI Pharma Inc.EFFECT - MEI Pharma, Inc. (0001262104) (Filer)
- SECSEC Form 424B3 filed by MEI Pharma Inc.424B3 - MEI Pharma, Inc. (0001262104) (Filer)
- SECMEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - MEI Pharma, Inc. (0001262104) (Filer)
- SECAmendment: SEC Form S-3/A filed by MEI Pharma Inc.S-3/A - MEI Pharma, Inc. (0001262104) (Filer)
- INSIDERSEC Form 4 filed by Director Riezman Joshua4 - MEI Pharma, Inc. (0001262104) (Issuer)
- INSIDERSEC Form 3 filed by new insider Riezman Joshua3 - MEI Pharma, Inc. (0001262104) (Issuer)
- SECSEC Form S-3 filed by MEI Pharma Inc.S-3 - MEI Pharma, Inc. (0001262104) (Filer)
- SECMEI Pharma Inc. filed SEC Form 8-K: Leadership Update8-K - MEI Pharma, Inc. (0001262104) (Filer)
- SECMEI Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MEI Pharma, Inc. (0001262104) (Filer)
- PRMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR AdvisingMEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or "the Company") today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and long-term capital innovation. This strategic move, developed in partnership with GSR and with guidance provided by Litecoin Creator and MEI Board member Charlie Lee, marks the beginning of MEI's broader institutional treasury ini
- SECMEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - MEI Pharma, Inc. (0001262104) (Filer)
- INSIDERNew insider Lee Charles Benjamin claimed ownership of 292,397 shares (SEC Form 3)3 - MEI Pharma, Inc. (0001262104) (Issuer)
- SECSEC Form 424B5 filed by MEI Pharma Inc.424B5 - MEI Pharma, Inc. (0001262104) (Filer)
- SECMEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Leadership Update, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - MEI Pharma, Inc. (0001262104) (Filer)
- PRMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeCharlie Lee, the Founder of Litecoin and a lead investor in the PIPE, has joined the Board of Directors of the Company GSR, a preeminent digital asset market maker and lead investor in the private placement, has been appointed to act as the treasury's Asset Manager MEI Pharma will use 100% of the net proceeds to launch its treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company" or "MEI") today announced that it has closed its previously announced private placement for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a pric
- PRMEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeCharlie Lee, the Founder of Litecoin and a lead investor in the PIPE, will join the Board of Directors of the Company effective upon the closing of the Private Placement GSR, a preeminent digital asset market maker and lead investor in the private placement, is appointed to act as the treasury's Asset Manager MEI Pharma will use 100% of the net proceeds to launch its treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company" or "MEI") today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale
- INSIDERSEC Form 4 filed by Director Wood Steven D4 - MEI Pharma, Inc. (0001262104) (Issuer)
- INSIDERSEC Form 4 filed by Director Reynolds Thomas C4 - MEI Pharma, Inc. (0001262104) (Issuer)
- INSIDERSEC Form 4 filed by Director Glover Nicholas4 - MEI Pharma, Inc. (0001262104) (Issuer)
- INSIDERSEC Form 4 filed by Director Flynn James P4 - MEI Pharma, Inc. (0001262104) (Issuer)
- INSIDERSEC Form 4 filed by Secretary, Acting CEO & CFO File Justin J.4 - MEI Pharma, Inc. (0001262104) (Issuer)
MEIP FAQ
8 questionsWhat does MEI Pharma Inc. do?
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor...What is the latest news on MEIP?
Quantisnow has not tracked any new filings, ratings or press releases for MEIP in the last 30 days. The most recent wire item was published on September 15, 2025.Where does MEIP stock trade?
MEI Pharma Inc. (MEIP) is listed on NASDAQ.What sector and industry is MEIP in?
MEI Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MEI Pharma Inc. go public?
MEI Pharma Inc. (MEIP) completed its IPO in 2003.What are analysts saying about MEIP?
Across the last 5 analyst actions on MEI Pharma Inc., there were 0 upgrades and 4 downgrades. The most recent action was from Laidlaw: Hold on 2024-07-23. Recent price targets range from $1.00 to $4.00.What companies are similar to MEIP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MEIP side-by-side with any of them on Quantisnow.How can I track MEIP on Quantisnow?
Quantisnow aggregates MEI Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MEIP to receive live email and push alerts on every new disclosure.